The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
On February 25, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) has concluded its inspection of the company’s API manufacturing facility in Bollaram, Hyderabad. The inspection, initially reported on November 19, 2024, has been classified as Voluntary Action Indicated (VAI), and the inspection status is now closed. This development is a positive outcome for Dr. Reddy’s, as it indicates compliance with regulatory standards, potentially enhancing its reputation and operational stability in the pharmaceutical industry.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the production of generic medications, active pharmaceutical ingredients (APIs), and proprietary products, with a significant focus on the global market, including the United States.
YTD Price Performance: -13.91%
Average Trading Volume: 1,836,827
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.2B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.